Carlos Freeman

We need to be cautious here. The psychedelic research arena is vastly becoming warped and incentivised with the luxurious lure of high value industry, and this can be naturally blinding to a degree, you can't see what is lurking in the shadows. On the balance of probability, the Psychedelic Research and Therapy industry is being intentionally weaponized by state-governments as a core component of the pipeline of "biomedical erasure." This weaponization is not the result of an accidental convergence of interests, but the natural, highly optimized output of two desperate, symbiotic systems. The UK state apparatus (for example), crippled by the thermodynamic entropy of a chronically ill population and insurmountable financial debt dictated by QIPP, requires a mechanism to legally and administratively erase organic disease from its expensive medical ledgers. Concurrently, the venture-capital-backed psychedelic industry, burdened by massive speculative valuations and the TESCREAL ideology of rapid disruption, requires a vast, transdiagnostic patient population to justify its monopolistic existence. The synthesis of these dual imperatives is the aggressive psychologization of somatic disease. By leveraging the theoretical architectures of the REBUS model and systematically targeting the Medically Unexplained Symptoms (MUS) demographic, "Corporadelia" provides any state public health infrastructure with the ultimate thermodynamic deception. The administration of proprietary, functionally unblinded hallucinogens within the low-cost IAPT infrastructure serves to forcefully overwrite a patient's biological reality, convincing them that their organic pathology is merely trauma or a predictive coding error.